A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...

Editor Sofia Lind questions the lack of planning, support and infrastructure for GPs among the rollout of tirzepatide in ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP-1) receptor agonists, reducing their effectiveness for weight loss, ...

Of the 102,166 GLP-1s analyzed, 94% had some form of commercial insurance, yet cost-saving options were still widely overlooked.

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

The weight-loss injection boom that swept through Hollywood and boardrooms alike is now facing a potentially deadly reckoning ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, respectively. What's more, obesity alone as an indication bars coverage ...